Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Appendicitis | 11 | 2025 | 15 | 3.750 |
Why?
|
| Anti-Bacterial Agents | 9 | 2025 | 73 | 2.710 |
Why?
|
| Appendectomy | 11 | 2025 | 13 | 1.840 |
Why?
|
| Emergency Service, Hospital | 1 | 2025 | 64 | 0.910 |
Why?
|
| Soft Tissue Infections | 3 | 2024 | 7 | 0.800 |
Why?
|
| Humans | 19 | 2025 | 6794 | 0.610 |
Why?
|
| Esophageal Fistula | 1 | 2018 | 1 | 0.550 |
Why?
|
| Surgical Stomas | 1 | 2018 | 2 | 0.550 |
Why?
|
| Esophagus | 1 | 2018 | 13 | 0.550 |
Why?
|
| Stents | 1 | 2018 | 13 | 0.550 |
Why?
|
| Severity of Illness Index | 4 | 2024 | 118 | 0.510 |
Why?
|
| Laparoscopy | 2 | 2020 | 21 | 0.500 |
Why?
|
| Sodium | 1 | 2015 | 43 | 0.460 |
Why?
|
| Hyponatremia | 1 | 2015 | 20 | 0.460 |
Why?
|
| Biomarkers | 2 | 2013 | 214 | 0.450 |
Why?
|
| Adult | 12 | 2024 | 2113 | 0.410 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 19 | 0.400 |
Why?
|
| Arterioles | 1 | 2012 | 8 | 0.390 |
Why?
|
| Microvessels | 1 | 2012 | 3 | 0.380 |
Why?
|
| Treatment Outcome | 8 | 2024 | 500 | 0.380 |
Why?
|
| Female | 13 | 2024 | 4060 | 0.370 |
Why?
|
| Male | 13 | 2024 | 3671 | 0.370 |
Why?
|
| Terpenes | 1 | 2011 | 1 | 0.360 |
Why?
|
| Exhalation | 1 | 2011 | 3 | 0.360 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2011 | 3 | 0.360 |
Why?
|
| Breath Tests | 1 | 2011 | 7 | 0.350 |
Why?
|
| Middle Aged | 10 | 2024 | 2108 | 0.350 |
Why?
|
| Lung | 1 | 2011 | 106 | 0.320 |
Why?
|
| Retrospective Studies | 8 | 2021 | 681 | 0.320 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2010 | 2 | 0.320 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2010 | 9 | 0.310 |
Why?
|
| Heart Diseases | 1 | 2010 | 9 | 0.310 |
Why?
|
| Postoperative Complications | 4 | 2020 | 109 | 0.310 |
Why?
|
| Bilirubin | 2 | 2016 | 4 | 0.250 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2016 | 8 | 0.250 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2016 | 7 | 0.240 |
Why?
|
| Acute Disease | 5 | 2021 | 91 | 0.230 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2024 | 1 | 0.210 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 35 | 0.200 |
Why?
|
| Prognosis | 3 | 2016 | 220 | 0.200 |
Why?
|
| Necrosis | 3 | 2024 | 30 | 0.200 |
Why?
|
| Time Factors | 2 | 2012 | 321 | 0.170 |
Why?
|
| Appendix | 1 | 2020 | 1 | 0.170 |
Why?
|
| Length of Stay | 5 | 2021 | 53 | 0.170 |
Why?
|
| Young Adult | 3 | 2019 | 567 | 0.160 |
Why?
|
| Hospitalization | 2 | 2020 | 128 | 0.160 |
Why?
|
| Risk Factors | 3 | 2024 | 767 | 0.150 |
Why?
|
| Conservative Treatment | 1 | 2019 | 10 | 0.150 |
Why?
|
| Debridement | 2 | 2021 | 5 | 0.150 |
Why?
|
| Laparotomy | 1 | 2018 | 2 | 0.140 |
Why?
|
| Aged | 4 | 2024 | 1539 | 0.140 |
Why?
|
| Animals | 2 | 2012 | 1875 | 0.130 |
Why?
|
| Metronidazole | 1 | 2016 | 3 | 0.130 |
Why?
|
| beta-Lactams | 1 | 2016 | 2 | 0.130 |
Why?
|
| Cephalosporins | 1 | 2016 | 4 | 0.130 |
Why?
|
| Leukocyte Count | 1 | 2016 | 10 | 0.130 |
Why?
|
| Cholangitis | 1 | 2016 | 4 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 82 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 8 | 0.130 |
Why?
|
| Intraoperative Care | 1 | 2016 | 4 | 0.130 |
Why?
|
| Gallstones | 1 | 2016 | 6 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2016 | 44 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2016 | 89 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 7 | 0.120 |
Why?
|
| Pancreatitis | 1 | 2016 | 108 | 0.110 |
Why?
|
| Patient Readmission | 3 | 2021 | 24 | 0.110 |
Why?
|
| Cholecystitis, Acute | 1 | 2014 | 3 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 268 | 0.100 |
Why?
|
| Lactic Acid | 1 | 2013 | 8 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 104 | 0.100 |
Why?
|
| Logistic Models | 1 | 2013 | 165 | 0.100 |
Why?
|
| Cricetinae | 1 | 2012 | 11 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 1 | 2012 | 7 | 0.100 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 17 | 0.100 |
Why?
|
| Free Tissue Flaps | 1 | 2012 | 7 | 0.100 |
Why?
|
| Quality of Life | 3 | 2020 | 184 | 0.090 |
Why?
|
| United States | 3 | 2024 | 1019 | 0.090 |
Why?
|
| Chromatography, Gas | 1 | 2011 | 1 | 0.090 |
Why?
|
| Volatilization | 1 | 2011 | 1 | 0.090 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2011 | 2 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2011 | 26 | 0.090 |
Why?
|
| Rats, Wistar | 1 | 2011 | 55 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 127 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 231 | 0.080 |
Why?
|
| Rats | 1 | 2011 | 571 | 0.080 |
Why?
|
| Plasmapheresis | 1 | 2010 | 1 | 0.080 |
Why?
|
| von Willebrand Factor | 1 | 2010 | 1 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 57 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 79 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 64 | 0.080 |
Why?
|
| Administration, Intravenous | 2 | 2020 | 9 | 0.070 |
Why?
|
| Child | 2 | 2019 | 524 | 0.060 |
Why?
|
| Adolescent | 2 | 2019 | 869 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 112 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2024 | 197 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2024 | 331 | 0.050 |
Why?
|
| Lithiasis | 1 | 2021 | 1 | 0.040 |
Why?
|
| Antimicrobial Stewardship | 1 | 2021 | 2 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 33 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 36 | 0.040 |
Why?
|
| Absenteeism | 1 | 2020 | 1 | 0.040 |
Why?
|
| Fecal Impaction | 1 | 2020 | 1 | 0.040 |
Why?
|
| Los Angeles | 1 | 2021 | 321 | 0.040 |
Why?
|
| Health Status | 1 | 2020 | 83 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 3 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 280 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 5 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2019 | 18 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 50 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 55 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2019 | 258 | 0.040 |
Why?
|
| Linear Models | 1 | 2017 | 41 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 41 | 0.030 |
Why?
|
| Outpatients | 1 | 2016 | 10 | 0.030 |
Why?
|
| Decompression, Surgical | 1 | 2016 | 4 | 0.030 |
Why?
|
| Longevity | 1 | 2016 | 7 | 0.030 |
Why?
|
| Patient Admission | 1 | 2016 | 10 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2016 | 17 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 48 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 84 | 0.030 |
Why?
|
| Pain | 1 | 2016 | 38 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 111 | 0.030 |
Why?
|
| Conversion to Open Surgery | 1 | 2014 | 1 | 0.030 |
Why?
|
| Emergencies | 1 | 2014 | 11 | 0.030 |
Why?
|
| Comorbidity | 1 | 2014 | 147 | 0.030 |
Why?
|